Enveda Raises $311M To Push AI-Discovered Medicines Deeper Into Trials
Frontier Enterprise reported that Enveda closed a $311 million round led by Catalio Capital Management after two early clinical readouts for PRISM-discovered medicines.
Enveda has secured $311 million to carry its AI-discovered drug pipeline into deeper clinical work, Frontier Enterprise reported, giving the clinical-stage biotechnology company fresh capital after two early readouts in 2026.
Catalio Capital Management led the financing.
The investor group combines new backers such as Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, T. Rowe Price-advised accounts, Digitalis Ventures, a sovereign wealth fund and Alderline Group with returning shareholders including Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital and Lux Capital.
The transaction lifts Enveda’s total capital raised above $845 million and brings Catalio co-founder and managing partner George Petrocheilos onto the company’s board.
For a biotech built around AI drug discovery, the round moves the story from platform promise toward the more expensive test of clinical execution.
Clinical Readouts Set The Funding Context
The financing follows two positive early clinical readouts this year for medicines Enveda found with PRISM, its AI foundation model trained on chemistry from living organisms.
The source identifies the early areas as atopic dermatitis and metabolic health, both tied to compounds discovered through the platform rather than conventional molecule design.
The proceeds are assigned to a specific development agenda.
ENV-294 and ENV-308 are slated for later-stage trials and additional indications, with new studies expected in the coming months.
ENV-6946 is expected to move through mid-phase trials, while additional programs for inflammatory and metabolic conditions enter the clinic.
That spending plan makes the round more than a balance-sheet event.
It defines the next test for Enveda: whether a model trained on natural chemistry can keep producing drug candidates that survive human testing beyond the earliest signals.
PRISM Starts From Natural Chemistry
Enveda’s approach starts with the premise that living systems contain useful chemistry that has been difficult to examine at industrial scale.
The source says molecules from nature account for almost one in two oral medicines, while about 99% of natural chemical diversity remains unexplored because compound isolation, identification and testing have been slow and costly.
PRISM is designed to search that space.
The model looks for molecules present in plants, microbes and the human body, infers structures from mass spectrometry data, steers lab experiments that test biological function and prioritizes the candidates with the strongest therapeutic potential.
The company’s scientists then turn the most promising starting points into oral medicines with drug-like characteristics.
The central wager is that molecules shaped by evolution to work inside living systems may avoid some toxicity and bioavailability problems that can limit synthetic drug candidates.
Founder and CEO Viswa Colluru framed the company’s premise around that difference, saying AI now lets Enveda read chemistry that living things have refined for billions of years and that two novel molecules from the approach have shown early potential in people.
Since 2019, the platform has generated 17 development candidates.
Three are now in human trials, each with a first-in-class mechanism aimed at large underserved populations affected by common diseases.
The new funding puts those candidates and the next wave of PRISM-derived programs under a broader clinical timetable rather than leaving the platform as a discovery claim.
